Navigation Links
Akela Pharma initiates its first abuse deterrent opioid Phase I clinical trial
Date:3/6/2008

focused on developing therapies for the growing multi-billion dollar inhalation and pain markets. Its lead product, for the treatment of breakthrough cancer pain, is a fast-acting Fentanyl formulation delivered using the Company's TAIFUN(R) dry powder inhaler platform. Its pipeline also includes therapeutics for asthma, COPD, growth hormone deficiencies and controlled substance abuse deterrent formulations.

Akela's common shares trade on The Toronto Stock Exchange ("TSX") under the symbol "AKL" with 11.7 million shares outstanding.

This news release contains certain forward-looking statements that reflect the current views and/or expectations of Akela Pharma Inc. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.


'/>"/>
SOURCE Akela Pharma Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Akela Pharma receives letter from the FDA regarding its pre-clinical toxicology studies for Fentanyl TAIFUN(R)
2. Akela Pharma provides corporate update
3. Akela Pharma announces final positive results from its growth hormone releasing hormone (GHRH) Phase II trial
4. Akela Pharma reports results for third quarter of fiscal 2007
5. AKELA Pharma Inc. announces U.S. public offering and proposed listing
6. Akela Pharma Inc. Completes Share Consolidation
7. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
8. MinuteClinic Hits 500th Clinic Mark; New Locations Open in Dallas, Los Angeles and Orlando CVS/pharmacy Stores
9. Notice of Bradmer Pharmaceuticals Conference Call
10. Transcept Pharmaceuticals to Present at Cowen and Companys 27th Annual Health Care Conference in Boston
11. Catalyst Pharmaceutical Partners, Inc. Names Director - Corporate Clinical Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/21/2014)... York (PRWEB) December 21, 2014 ... other product liability claims involving a class of ... continue to move forward in a federal multidistrict ... District of California, Bernstein Liebhard LLP reports. According ... has established a data cut-off date of February ...
(Date:12/21/2014)... AlignLife of Norton Shores is spreading Christmas ... time helping people get their health back. Mission for ... serving those persons in Muskegon County who are unable to ... of life. Dr. Michael Rykse wanted to do a Toy ... and he knew he found that when he heard what ...
(Date:12/21/2014)... Portland, OR (PRWEB) December 21, 2014 ... discussing some of the issues and systemic barriers for ... ITU World Paratriathlon Champion. Scheidies has a condition called ... over time. He describes how he adapted his athletic ... to use his success in triathlon to pioneer the ...
(Date:12/21/2014)... The Oncology Institute of Hope and Innovation hosted their ... offices. The Hope for the Holidays Toy Drive is a ... families during the holiday season. This year, the toy drive ... both offices. This event continues to be successful year after ... store managers and assistant managers came out and not only ...
(Date:12/20/2014)... a distinguished special dress supplier, has just done something ... cut prices to all its prom dresses already, offering ... Many of the hottest styles are sold here like ... more. , A spokesman for MissyDress says, “The great ... prom dresses or sweetheart chiffon prom dresses, you will ...
Breaking Medicine News(10 mins):Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 2Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 3Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 4Health News:AlignLife of Norton Shores Makes a Brighter Christmas for Kids in Muskegon 2Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 2Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 3Health News:MissyDress: The Prices of Prom Dresses Just Reduced 2
... ... found that women taking AdvaCAL® calcium had the highest bone density increase among 32 ... postmenopausal women, 79 skeletal measures and 7 different types of calcium, including dairy calcium. ... (PRWEB) January ...
... , ... Bone marrow is a leading source of adult stem cells, ... cells is an arduous and often painful process. Now, researchers have found ... new source of valuable and easy-to-obtain regenerative cells called hematopoietic stem and ...
... ... connectors, is utilizing their nano-connector Bi-lobes® to help handle difficult signal routing and ... ... the leading manufacturer of miniature high-rel connectors, is utilizing their nano-connector Bi-lobes® to ...
... ... areas shows that current KOL identification methods produce inaccurate results; relationship models are more ... ... white paper challenges the generally-held notion that scientists who are “productive” in terms ...
... Center have performed the first complete genomic sequencing of ... lead to personalized treatments based on the unique biological ... may unveil new molecular targets for which more effective ... study also may lead to new and better ways ...
... ... ... attract high-value patients, get book deals, CNN expert spots, lucrative speaking engagements, and earn ten ... report high-visibility doctors are as adept at publicity and personal branding as any Hollywood film ...
Cached Medicine News:Health News:Report: AdvaCALCalcium Builds Bone Best 2Health News:Fat Tissue May Be a Source of Valuable Blood Stem Cells, Study Says 2Health News:Fat Tissue May Be a Source of Valuable Blood Stem Cells, Study Says 3Health News:Fat Tissue May Be a Source of Valuable Blood Stem Cells, Study Says 4Health News:Omnetics Nano-to-Flex Connectors Solve Big Problems in Small Spaces 2Health News:Standard Methods Miss 50% of Pharmaceutical Key Opinion Leaders 2Health News:Standard Methods Miss 50% of Pharmaceutical Key Opinion Leaders 3Health News:UCLA cancer researchers perform complete genomic sequencing of brain cancer cell line 2Health News:UCLA cancer researchers perform complete genomic sequencing of brain cancer cell line 3Health News:Doctors: Memorable or Forgettable? 4 Steps to a High Visibility Practice 2Health News:Doctors: Memorable or Forgettable? 4 Steps to a High Visibility Practice 3
(Date:12/19/2014)... Dec. 18, 2014   Aratana Therapeutics, Inc ... company focused on the licensing, development and commercialization ... positive results from its pivotal field study of ... pain in dogs with osteoarthritis.  In the study, ... scores that were statistically significant compared to placebo ...
(Date:12/19/2014)... development with the growth pace keeping at 20%-30% in last ... size of China separating membrane products ... 16.3%. It is projected that China ... 20% in the upcoming years and that the figure by ... integrated membrane industrial system has taken shape in ...
(Date:12/17/2014)... Los beneficios y ganancias están ... de gasto en investigación y desarrollo   ... de septiembre de 2014) ZEISS aumentó sus ingresos en ... (año anterior: 4.190 millones de euros) a pesar de ... crecieron un 14 por ciento, a 360 millones de ...
Breaking Medicine Technology:Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 2Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 3ZEISS confirma su posición en un entorno difícil 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: